Literatura científica selecionada sobre o tema "Natrium Iodide Symporter (NIS)"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Consulte a lista de atuais artigos, livros, teses, anais de congressos e outras fontes científicas relevantes para o tema "Natrium Iodide Symporter (NIS)".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Artigos de revistas sobre o assunto "Natrium Iodide Symporter (NIS)"
Elliyanti, Aisyah, Rony Rustam, Tofrizal Tofrizal, Yenita Yenita e Yayi D. Billianti Susanto. "Evaluating the Natrium Iodide Symporter Expressions in Thyroid Tumors". Open Access Macedonian Journal of Medical Sciences 9, B (5 de janeiro de 2021): 18–23. http://dx.doi.org/10.3889/oamjms.2021.5534.
Texto completo da fonteElliyanti, Aisyah, Tenny Putri Wikayani, Noormartany, Johan S. Masjhur e Tri Hanggono Achmad. "Deteksi Natrium/Iodide Symporter (NIS) pada Galur Sel Kanker Payudara SKBR3 dengan Imunositofluoresens". Majalah Kedokteran Bandung 48, n.º 1 (2016): 15–18. http://dx.doi.org/10.15395/mkb.v48n1.728.
Texto completo da fonteElliyanti, Aisyah. "Deteksi Natrium/Iodide Symporter (NIS) pada Galur Sel Kanker Payudara SKBR3 dengan Imunositofluoresens". Majalah Kedokteran Bandung 48, n.º 1 (2016): 15–18. http://dx.doi.org/10.15395/mkb.v48n1.728.1.
Texto completo da fonteElliyanti, Aisyah, Tenny Putri Wikayani, Noormartany, Johan S. Masjhur e Tri Hanggono Achmad. "Deteksi Natrium/Iodide Symporter (NIS) pada Galur Sel Kanker Payudara SKBR3 dengan Imunositofluoresens". Majalah Kedokteran Bandung 48, n.º 1 (março de 2016): 15–18. http://dx.doi.org/10.15395/mkb.v48n1.729.
Texto completo da fonteElliyanti, Aisyah, Andani Eka Putra, Yunia Sribudiani, Noormartany Noormartany, Johan S. Masjhur, Tri Hanggono Achmad e Dachriyanus Dachriyanus. "Epidermal Growth Factor and Adenosine Triphosphate Induce Natrium Iodide Symporter Expression in Breast Cancer Cell Lines". Open Access Macedonian Journal of Medical Sciences 7, n.º 13 (6 de agosto de 2019): 2088–92. http://dx.doi.org/10.3889/oamjms.2019.620.
Texto completo da fonteSpitzweg, C. "Der Natrium-Iodid-Symporter (NIS): Bedeutung für die Bildgebung und therapeutische Optionen". Der Nuklearmediziner 30, n.º 1 (março de 2007): 19–30. http://dx.doi.org/10.1055/s-2006-955219.
Texto completo da fonteLisco, Giuseppe, Anna De Tullio, Vito Angelo Giagulli, Giovanni De Pergola e Vincenzo Triggiani. "Interference on Iodine Uptake and Human Thyroid Function by Perchlorate-Contaminated Water and Food". Nutrients 12, n.º 6 (4 de junho de 2020): 1669. http://dx.doi.org/10.3390/nu12061669.
Texto completo da fontePerone, Denise, Silvânia S. Teixeira, Sueli A. Clara, Daniela C. dos Santos e Célia R. Nogueira. "Aspectos genéticos do hipotireoidismo congênito". Arquivos Brasileiros de Endocrinologia & Metabologia 48, n.º 1 (fevereiro de 2004): 62–69. http://dx.doi.org/10.1590/s0004-27302004000100008.
Texto completo da fonteSpitzweg, C. "Der Natrium-Jodid-Symporter (NIS)". Der Internist 44, n.º 4 (4 de março de 2003): 396–411. http://dx.doi.org/10.1007/s00108-003-0877-9.
Texto completo da fonteVan Sande, J., C. Massart, R. Beauwens, A. Schoutens, S. Costagliola, J. E. Dumont e J. Wolff. "Anion Selectivity by the Sodium Iodide Symporter". Endocrinology 144, n.º 1 (1 de janeiro de 2003): 247–52. http://dx.doi.org/10.1210/en.2002-220744.
Texto completo da fonteTeses / dissertações sobre o assunto "Natrium Iodide Symporter (NIS)"
Farnedi, Anna <1973>. "Caratterizzazione genetico-funzionale del carcinoma mammario. Valutazione dell’espressione di NIS (Natrium/Iodide Symporter)". Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2008. http://amsdottorato.unibo.it/991/1/Tesi_Farnedi_Anna.pdf.
Texto completo da fonteFarnedi, Anna <1973>. "Caratterizzazione genetico-funzionale del carcinoma mammario. Valutazione dell’espressione di NIS (Natrium/Iodide Symporter)". Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2008. http://amsdottorato.unibo.it/991/.
Texto completo da fonteLacoste, Claire. "Le transporteur d’iode NIS dans la carcinogenèse non thyroïdienne : nouvelles fonctions, nouveaux enjeux". Thesis, Paris 11, 2011. http://www.theses.fr/2011PA11T043.
Texto completo da fonteThe Natrium iodide symporter (NIS) is a transmembrane glycoprotein known for its role in thyroid hormones biosynthesis, catalyzes active iodide transport in the thyroid. The iodide transport activity of NIS allows its clinical applications for diagnosis, follow-up using radio-isotopic imaging and treatment by 131I radiotherapy of thyroid cancers. Several studies described NIS expression in non thyroidal tumour tissues frequently displaying a cytoplasmic localization. In the current study, we reveal that, independently to its transport activity, NIS habors new biological functions in migration and invasion through RhoGTPase signalling pathway, a pathway involved in carcinogenesis. In addition, we establish that NIS is a tight junction-associated protein, which dynamically shuttles between tight junctions and cytoplasm during cell migration, and localizes at the leading edge of the metastatic cancer cells. Overall, these findings offer a novel appraisal of the potential role of NIS in carcinogenesis, and of the factors governing NIS intracellular trafficking
Kessel, Anne-Liese. "Der Natrium-Iodid-Symporter (NIS) als neues therapeutisches Gen zur Behandlung des Malignen Melanoms". Diss., lmu, 2010. http://nbn-resolving.de/urn:nbn:de:bvb:19-118310.
Texto completo da fonteKolokythas, Marie-Christine [Verfasser], e Christine [Akademischer Betreuer] Spitzweg. "Molekulare Bildgebung und gezielte Radionuklidtherapie extrathyreoidaler Tumore nach Stammzell-basiertem Natrium/Iodid-Symporter (NIS) - Gentransfer / Marie-Christine Kolokythas ; Betreuer: Christine Spitzweg". München : Universitätsbibliothek der Ludwig-Maximilians-Universität, 2019. http://d-nb.info/1190563576/34.
Texto completo da fonteFenniche, Salma. "Rôle de la NADPH OXYDASE NOX4 dans la régulation de l'expression et de l'activité de CHD4 dans les tumeurs thyroïdiennes porteuses de la mutation BRAFV600E". Electronic Thesis or Diss., université Paris-Saclay, 2024. http://www.theses.fr/2024UPASL022.
Texto completo da fonteMetabolic radiotherapy with radioiodine is the cornerstone of the treatment of distant metastases of differentiated thyroid cancers. This therapy depends on the expression at the basal membrane of thyrocytes of the Natrium Iodide Symporter 'NIS'. BRAFV600E mutation is present in 45 to 60% of papillary thyroid carcinomas, which represent 80% of thyroid cancers. The presence of this mutation is associated with the most aggressive thyroid tumors with low levels or absence of NIS expression. The loss of radioactive iodine uptake translates into resistance to metabolic radiotherapy, constituting a major issue for the treatment of patients with this cancer. One approach for treating patients refractory to metabolic radiotherapy is to increase iodine uptake.At the transcriptional level, our team has already shown, through a comparative analysis concerning approximately 500 PTCs from the TCGA database, that NOX4 was strongly expressed in PTCs-BRAFV600E compared to PTCs-BRAFwt. However, at the protein level, no link has been established between the BRAFV600E mutation and NOX4 in malignant and non-malignant tumors (BRAFV600E/BRAFwt). In my thesis project, we illustrate for the first time a positive correlation between the presence of BRAFV600E mutation and the overexpression of NOX4 protein in PTC tumor tissues. The overexpression of NOX4 was associated with an aggressive nature of tumors. Furthermore, we showed that 60% of infiltrating C-PTCs overexpress NOX4 independently of BRAF mutational status, suggesting that NOX4 could be considered as a potential co-marker of PTC aggressiveness. Interestingly, NOX4 protein was also overexpressed in non-malignant thyroid diseases (Basedow, goiters, and hyperplasias), with different subcellular localizations, suggesting a role for NOX4 in progression to thyroid malignancy.Furthermore, on a mechanistic level, our team has previously shown that BRAFV600E controls the expression of NOX4 under the effect of TGF-β/SMAD3 and that NOX4-derived ROS contribute to the repression of NIS. Inhibition of NOX4 promotes reactivation of the NIS. This reversibility suggests a contribution to an epigenetic mechanism. CHD4, a subunit of the NuRD remodeling complex, plays an essential role in gene repression. it was found to be strongly expressed in PTCs, in which it was associated with a poor prognosis. In this study, we showed that the TGF-β/SMAD3 pathway regulates the expression of CHD4 protein. The latter cooperates with DNMTs in repressing NIS in several thyroid tumor cells lines mutated for BRAFV600E. Furthermore, we showed that CHD4 responds to oxidative DNA damage induced by NOX4-derived ROS. Indeed, inhibition of NOX4 or its functional partner p22phox reduces the recruitment of CHD4 to chromatin. This recruitment depends on OGG1 and MSH6, two proteins involved in oxidative DNA damage repair. This study identifies CHD4 as a new therapeutic candidate in radioiodine-refractory thyroid cancers
Gotthardt, Inka. "Interferenzen endokrin aktiver Substanzen mit der Hypothalamus-Hypophysen-Schilddrüsenachse". Doctoral thesis, Humboldt-Universität zu Berlin, Mathematisch-Naturwissenschaftliche Fakultät I, 2010. http://dx.doi.org/10.18452/16145.
Texto completo da fonteEndocrine active compounds (EACs) can be of natural or synthetic origin and show hormone-like effects that interfere with feedback regulation of hormonal networks. Interferences with the hypothalamic-pituitary-thyroid axis (HPT-axis) result in extensive consequences as thyroid hormones are essential for regulation of development, growth, and metabolism. In the work presented here, the active profile of potent inhibitors of the HPT-axis namely 4-methylbenzylidene-camphor (4-MBC) and genistein (GEN) was investigated. 4-MBC, a UV filter used in sunscreens and various cosmetics, was identified as a goiter causing agent using ovariectomized rats. 4-MBC acts at the level of hypothalamus and pituitary gland by modulating the expression of thyrotropin-releasing hormone (TRH) as well as thyroid-stimulating hormone (TSH) that regulate feedback on the HPT-axis. Furthermore, biosynthesis of thyroid hormones was impaired by 4-MBC secondary to the inhibition of iodide transport with concomitantly increased messenger RNA (mRNA)-levels of the sodium-iodide symporter (NIS). In parallel expression of the angiogenesis marker vascular endothelial growth factor (VEGF) was increased, indicating hypothyroidism. After the application of 4-MBC the expression of L-3,3’,5-triiodothyronine (T3)-regulated target genes was reduced in the periphery both on the mRNA and protein level. The documented species-specific effects indicate a difference in pharmacokinetics, possibly secondary to differential expression of cytochrome P450 genes. GEN is contained in soy and red clover and its mechanistic analysis was carried out in thyroid hormone receptor (TR) deficient mice (TRα0/0). The gender-dependent effects of GEN on tissue specificity did not follow an obvious pattern and warrant continuative analysis. The work presented here supports the assumption that EACs can interfere with function and regulation of the HPT-axis at levels that were previously considered safe.
Lin, Xiaoqin. "Regulation of sodium iodide symporter expression/function and tissue-targeted gene transfer of sodium iodide symporter". Connect to this title online, 2003. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1070462866.
Texto completo da fonteTitle from first page of PDF file. Document formatted into pages; contains xi, 123 p.; also includes graphics (some col.) Includes bibliographical references (p. 109-123). Available online via OhioLINK's ETD Center
Grünwald, Geoffrey. "Targeted delivery of the theranostic sodium iodide symporter (NIS) for cancer gene therapy". Diss., Ludwig-Maximilians-Universität München, 2013. http://nbn-resolving.de/urn:nbn:de:bvb:19-158988.
Texto completo da fonteLiu, Yu-Yu. "Modulation of Sodium/Iodide Symporter Expression and Function in Thyroid". The Ohio State University, 2011. http://rave.ohiolink.edu/etdc/view?acc_num=osu1293691026.
Texto completo da fonteCapítulos de livros sobre o assunto "Natrium Iodide Symporter (NIS)"
Kucharska, Anna M., Barbara Czarnocka e Urszula Demkow. "Anti-natrium/Iodide Symporter Antibodies and Other Anti-thyroid Antibodies in Children with Turner’s Syndrome". In Advances in Experimental Medicine and Biology, 131–38. Dordrecht: Springer Netherlands, 2012. http://dx.doi.org/10.1007/978-94-007-4549-0_17.
Texto completo da fonteGrimsdell, Ben, Adeel Saleem, Alessia Volpe e Gilbert O. Fruhwirth. "Genetic Engineering of Therapeutic Cells with the Sodium Iodide Symporter (NIS) to Enable Noninvasive In Vivo Therapy Tracking". In Methods in Molecular Biology, 303–30. New York, NY: Springer US, 2023. http://dx.doi.org/10.1007/978-1-0716-3499-8_18.
Texto completo da fonteElliyanti, Aisyah. "Radioiodine for Graves’ Disease Therapy". In Graves' Disease [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.96949.
Texto completo da fonteCarrasco, Nancy, e Rachel R. Kaspari. "Sodium/Iodide Symporter (NIS)". In Encyclopedia of Endocrine Diseases, 429–32. Elsevier, 2018. http://dx.doi.org/10.1016/b978-0-12-801238-3.96015-x.
Texto completo da fonteSpitzweg, Christine, e John C. Morris. "The Sodium–Iodide Symporter (NIS)". In Comprehensive Handbook of Iodine, 979–89. Elsevier, 2009. http://dx.doi.org/10.1016/b978-0-12-374135-6.00101-1.
Texto completo da fonte"NIS (sodium [Na]-iodide symporter)". In Encyclopedia of Genetics, Genomics, Proteomics and Informatics, 1348. Dordrecht: Springer Netherlands, 2008. http://dx.doi.org/10.1007/978-1-4020-6754-9_11428.
Texto completo da fonteJosefsson, Malin, e Eva Ekblad. "Sodium Iodide Symporter (NIS) in Gastric Mucosa". In Comprehensive Handbook of Iodine, 215–20. Elsevier, 2009. http://dx.doi.org/10.1016/b978-0-12-374135-6.00022-4.
Texto completo da fonteHernán Carro, Gerardo, e Juan Pablo Nicola. "The Molecular Basis for Radioiodine Therapy". In Thyroid Cancer - The Road From Genes to Successful Treatment [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.108073.
Texto completo da fonte"Correlation between natrium iodide symporter and c-fos expressions in breast cancer cell lines". In Advances in Biomolecular Medicine, editado por A. Elliyanti, N. Noormartany, J. S. Masjhur, Y. Sribudiani, A. M. Maskoen e T. H. Achmad, 19–22. CRC Press, 2017. http://dx.doi.org/10.1201/9781315208619-5.
Texto completo da fonteKnoop, Kerstin, Marie Kolokythas, Kathrin Klutz, Michael J. Willhauck, Nathalie Wunderlich, Dan Draganovici, Christian Zach et al. "Therapeutic Potential of Stem Cell-Mediated Sodium Iodide Symporter (NIS) Gene Delivery in Liver Cancer". In BASIC/TRANSLATIONAL - Thyroid Cancer, P2–679—P2–679. The Endocrine Society, 2011. http://dx.doi.org/10.1210/endo-meetings.2011.part3.p12.p2-679.
Texto completo da fonteTrabalhos de conferências sobre o assunto "Natrium Iodide Symporter (NIS)"
Fletcher, Alice, Rebecca Thompson, Martin Read, Andrew Turnell, Vicki Smith e Chris J. McCabe. "Abstract LB-327: Identification of novel sodium iodide symporter (NIS) interactors which modulate iodide uptake". In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-lb-327.
Texto completo da fonteKaraca, Turan. "Pendrin and sodium / iodide symporter (NIS) protein expression in testicular tissue of diabetic rat*". In 15th International Congress of Histochemistry and Cytochemistry. Istanbul: LookUs Scientific, 2017. http://dx.doi.org/10.5505/2017ichc.pp-167.
Texto completo da fonteDwyer, Roisin M., James Ryan, Ronan Havelin, John C. Morris, Cathal O'Flatharta, Brian Miller, Zhonglin Liu et al. "Abstract 5392: Mesenchymal stem cell (MSC) mediated delivery of the sodium iodide symporter (NIS) supports radionuclide imaging and treatment of breast cancer". In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-5392.
Texto completo da fonte